Comparative toxicokinetic (TK) and hydrolysis studies of intravenously administered two new antimalarial agents, artelinate (AL) and artesunate (AS), were performed in malaria-infected rats using three daily equimolar doses (96 micromoles/kg). The TK evaluation was related to select one drug for severe malaria treatment in U.S. Army. Drug concentration of AS with daily dose of 36.7 mg/kg was one-third less on day 3 than on day 1, which resembled its active metabolite, dihydroartemisinin (DHA), suggesting an autoinduction of hepatic drug-metabolizing enzymes for AS. The results were similar to other artemisinin drugs, but not for AL. TK parameters of AL were very comparable from day 1 to day 3 at same AS molecular dose at 40.6 mg/kg. AS is the prodrug of DHA with the DHA/AS ratio of 5.26 compared to the ratio of 0.01 for DHA/AL. Other TK parameters revealed that the total AUC1-3 days (84.4 microg.h ml-1) of AL was fivefold higher than that of AS (15.7 microg.h ml-1 of AS plus DHA). The elimination half-life of AL (7.1 h) was much longer than that of AS (0.36 h) or DHA (0.72 h). The remarkable alteration of the TK shape of AL may be caused by poor conversion rates to DHA and an enterohepatic circulation, which is confirmed by the present TK and tissue distribution studies. Compared to AS, higher drug exposure levels and longer exposure time of AL in the rat blood may be the cause of its increased toxicity.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10915810591007201DOI Listing

Publication Analysis

Top Keywords

artelinate artesunate
8
malaria-infected rats
8
day day
8
microgh ml-1
8
dha
5
toxicokinetics hydrolysis
4
hydrolysis artelinate
4
artesunate malaria-infected
4
rats comparative
4
comparative toxicokinetic
4

Similar Publications

Targeted nanodrug delivery systems are highly anticipated for the treatment of malaria. It is known that can induce new permeability pathways (NPPs) on the membrane of infected red blood cells (iRBCs) for their nutrient uptake. The NPPs also enable the uptake of nanoparticles (NPs) smaller than 80 nm.

View Article and Find Full Text PDF
Article Synopsis
  • The human malaria-monkey model has been a key tool in malaria research since 1966, helping to test the effectiveness and absorption of various antimalarial drugs.
  • Over the years, researchers have used this model to study both drug-resistant and drug-susceptible strains, mimicking human malaria infections closely.
  • The model has facilitated the development of key antimalarial treatments, including artemisinin-based combination therapies and the progression of tafenoquine to clinical trials, while also aiding in the understanding of malaria’s biology and drug resistance.
View Article and Find Full Text PDF

Medicinal herbs have proved along history to be a source of multiple cures. In this paper, we demonstrate how hydroxychloroquine can act as a good inhibitor of SARS-CoV-2 Spike protein receptor-binding-domain using molecular docking studies. We also unveil how hydroxychloroquine can interfere in the prevention of Lys353 in hACE2 from interacting with the corresponding binding hotspot present on the Spike protein.

View Article and Find Full Text PDF

Background: The US Army designed artelinate/lysine salt (AL) to overcome the instability of sodium artesunate in aqueous solution (AS). To select the most efficacious artemisinin treatment, direct comparison was performed in an uncomplicated non-human primate malaria model.

Methods: Splenectomized rhesus monkeys were inoculated with Plasmodium coatneyi and on day six, single equimolar loading dose of IV AL (11.

View Article and Find Full Text PDF

The artemisinin antimalarials cause embryo death and malformations in animals by killing embryonic erythroblasts. Groups of pregnant rats (N = 4) were administered 35 and 48 µmol/kg artesunate and 17.2, 28.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!